Results 11 - 20 of 26 : Previous 1 2 3 Next
The Competition Bites Trimeris
Rivals lead to lower sales of the pharmaceutical's only marketed drug.
MGI's Turn for "Strategic Alternatives"
MGI Pharma whispers those magic words.
Another drugmaker looks for a buyer.
QLT in a Rut or Ready for a Comeback?
QLT updates investors on its top drugs.
Actions speak louder than words.
Regeneron Sees Positive Phase 2 Data
Data from macular degeneration drug trial looks good.
EU approval opens new markets for the cancer drug that could edge out the competition by lowering overall medical costs.
There's fun in the sun and something to learn from West Coast Asset Management.
QLT announces sales results for its lead drug.
QLT opens up another share buyback plan.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK